Professor Yongsheng Wang: What Has Changed—and What Remains—in Breast Cancer Surgery?

Professor Yongsheng Wang: What Has Changed—and What Remains—in Breast Cancer Surgery?

Breast cancer has recently surpassed lung cancer as the most commonly diagnosed cancer among women worldwide. The status of regional lymph node involvement remains a key prognostic factor, directly influencing disease staging, treatment planning, and survival outcomes. While axillary lymph node dissection (ALND) has long been the standard for staging, it carries substantial morbidity. As modern breast surgery moves toward precision and minimally invasive approaches, sentinel lymph node biopsy (SLNB) has replaced ALND as the preferred axillary staging strategy, significantly reducing surgical trauma and complications.
Lymphoma Frontline Advances | Professor Qingqing Cai: Breakthrough Progress in First-Line Bispecific Antibody Therapy for Lymphoma — ASH 2025 Special

Lymphoma Frontline Advances | Professor Qingqing Cai: Breakthrough Progress in First-Line Bispecific Antibody Therapy for Lymphoma — ASH 2025 Special

The 2025 American Society of Hematology (ASH) Annual Meeting recently concluded in Orlando, USA, showcasing major breakthroughs in lymphoma research and offering new directions for optimizing clinical care. To translate cutting-edge science into clinical insight, Oncology Frontier – Hematology Frontier partners with Professor Qingqing Cai of Sun Yat-sen University Cancer Center to present the “Lymphoma Insights – ASH Special” series, delivering authoritative interpretation of landmark lymphoma studies with practical clinical relevance.
CASH 2026 | Professor Zhigang Cai: Breakthrough Advances in Clonal Hematopoiesis, MDS, MPN, and VEXAS Syndrome

CASH 2026 | Professor Zhigang Cai: Breakthrough Advances in Clonal Hematopoiesis, MDS, MPN, and VEXAS Syndrome

From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was successfully held in Tianjin. The meeting brought together leading international and national experts in hematology, focusing on frontier scientific advances and national health priorities, fostering deep academic exchange and shaping future directions of the discipline.
CASH 2026 | Professor Jian Li: Peking Union Medical College Hospital’s Experience in the Diagnosis and Treatment of AL Amyloidosis

CASH 2026 | Professor Jian Li: Peking Union Medical College Hospital’s Experience in the Diagnosis and Treatment of AL Amyloidosis

As the new year begins, leading experts gathered in Tianjin. From  January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was successfully held, bringing together top hematology specialists from China and abroad. The conference focused on cutting-edge scientific progress and national health priorities, fostering in-depth discussions on the future of hematology.
How to Develop Personalized Bladder-Preserving Strategies for MIBC? Professor Yijun Shen Shares MDT Experience and Clinical Decision Pathways

How to Develop Personalized Bladder-Preserving Strategies for MIBC? Professor Yijun Shen Shares MDT Experience and Clinical Decision Pathways

From January 10 to 11, 2026, the Beijing Young Urologic Oncology Physicians Academic Exchange Conference was successfully held in Beijing. The meeting brought together leading experts and young physicians in urologic oncology to discuss cutting-edge scientific advances and real-world clinical challenges, with the goal of fostering academic innovation and supporting the development of young clinicians.
Professor Lei Fan: The Evolving Landscape and Future Directions of First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) | 2026 CSCO Hematologic Oncology Conference

Professor Lei Fan: The Evolving Landscape and Future Directions of First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) | 2026 CSCO Hematologic Oncology Conference

From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. During the conference, Professor Lei Fan from Jiangsu Provincial People’s Hospital presented a comprehensive overview of the latest advances, current standards, and future directions in first-line treatment for chronic lymphocytic leukemia (CLL), offering valuable guidance for optimizing clinical management.
Professor Erlie Jiang: Platform Synergy, Evidence Empowerment, and Grassroots Equity — Outcomes of the 2025 CSCO Leukemia Guideline Roadshow and the 2026 Strategic Blueprint

Professor Erlie Jiang: Platform Synergy, Evidence Empowerment, and Grassroots Equity — Outcomes of the 2025 CSCO Leukemia Guideline Roadshow and the 2026 Strategic Blueprint

From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. Guided by the overarching vision of “Greater Hematology, Greater Public Health, and Greater Health,” CSCO’s hematology committees have built a four-pillar framework centered on standardization, clinical support, collaboration, and prognostic assessment, and a three-core value system emphasizing guideline implementation, resource decentralization, and academic empowerment.
Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?

Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?

The combination of antibody–drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) is rapidly transforming the clinical management of urothelial carcinoma. Meanwhile, circulating tumor DNA (ctDNA) is emerging as a highly promising biomarker, offering critical support for precision medicine and bladder-preserving treatment strategies.